$CRL

Charles River Laboratories (NYSE: CRL) CEO Birgit Girshick, in an interview, said the company will re-accelerate growth with a sharper focus on regulated safety assessment, expanded client data sharing, and non-animal testing. She discussed CRL’s two 2024 divestitures, its “Pathway to Purpose” strategy, and a deeper data-sharing partnership with Eli Lilly (NYSE: LLY).

Charles River Laboratories International (CRL) reported Q2 revenue of $1,004.08 million and a net loss of $1.48 million. The company lowered its 2026 GAAP EPS guidance to $3.05 to $3.35 and projected a 2.5% to 3.5% revenue decline, citing divestiture-related losses. Management said organic revenue growth is returning in its Discovery and Safety Assessment segment.

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

Girshick Birgit (Chief Executive Officer) sold 6,500 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $279.90 ($1.82M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 3,714 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $279.66 ($1.04M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

FOSTER JAMES C sold 28,733 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $275.00 ($7.90M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Knell Michael Gunnar (SVP, Finance and CAO) sold 6,645 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at an average of $260.38 ($258.53–$265.17, $1.73M total) across 9 trades on 2026-08-06.

Creamer Victoria L (EVP & Chief People Officer) sold 4,179 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $259.16 ($1.08M total) on 2026-08-06.

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.